Concepedia

Publication | Open Access

Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer

DOIFull Paper Access

316

Citations

15

References

2023

Year

Kathleen N. Moore, Antoine Angelergues, Gottfried E. Konecny, Yolanda García García, Susana Banerjee, Domenica Lorusso, Jung‐Yun Lee, John W. Moroney, Nicoletta Colombo, A. Roszak,
New England Journal of Medicine

Abstract

Among participants with platinum-resistant, FRα-positive ovarian cancer, treatment with MIRV showed a significant benefit over chemotherapy with respect to progression-free and overall survival and objective response. (Funded by ImmunoGen; MIRASOL ClinicalTrials.gov number, NCT04209855.).

References

YearCitations

Page 1